newsfilter
← Latest News
Business Wire·

Biocept's CNSide™ Cerebrospinal Fluid Assay Featured in Two Oral Presentations at the 2023 SNO/ASCO CNS Cancer Conference

Biocept, Inc. (NASDAQ:BIOC) ("Biocept" or the "Company"), a leading provider of molecular diagnostic assays, products and services, announces that its CNSide cerebrospinal fluid assay was featured in two oral